RS
ALNY icon

R Squared’s Alnylam Pharmaceuticals ALNY Stock Holding History

R Squared’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,660
Closed -$757K – 523
2025
Q3 		$757K Buy
+1,660
New +$676K 0.33% 66
2025
Q1 		– Sell
-140
Closed -$32.9K – 337
2024
Q4 		$32.9K Buy
+140
New +$36.8K 0.03% 664

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

R Squared's ALNY Position: Q4 2025 in Review

R Squared sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2025, closing a stake of 1,660 shares — an estimated $757K sold.

R Squared first reported a position in ALNY in Q4 2024 and held it in 2 quarters. The position peaked at $757K in Q3 2025. 851 funds tracked by Wall St. Rank hold ALNY as of Q4 2025.

  • R Squared reported no remaining Alnylam Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • R Squared sold 1,660 Alnylam Pharmaceuticals shares in Q4 2025, an estimated $757K.
  • R Squared first reported a position in Alnylam Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • R Squared's Alnylam Pharmaceuticals position peaked at $757K in Q3 2025.
  • 851 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2025.

Based on R Squared's 13F filing for Q4 2025, filed 30 Jan 2026.